List of Excipients in API tazarotene
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing tazarotene
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Allergan Inc | TAZORAC | tazarotene | 0023-8335 | ASCORBIC ACID | |
| Allergan Inc | TAZORAC | tazarotene | 0023-8335 | BENZYL ALCOHOL | |
| Allergan Inc | TAZORAC | tazarotene | 0023-8335 | BUTYLATED HYDROXYANISOLE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing tazarotene
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 | BENZYL ALCOHOL |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 | CARBOMER COPOLYMER TYPE B |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 | CARBOMER HOMOPOLYMER TYPE B |
| >Company | >Ingredient | >NDC | >Excipient |
Detailed excipient profiles for tazarotene
Excipient focus: ANHYDROUS CITRIC ACID
tazarotene drug variants containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: ASCORBIC ACID
tazarotene drug variants containing ASCORBIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing ASCORBIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
Excipient focus: BENZYL ALCOHOL
tazarotene drug variants containing BENZYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing BENZYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| Mayne Pharma | tazarotene | 51862-295 |
| Physicians Total Care Inc | tazarotene | 54868-4456 |
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYLATED HYDROXYANISOLE
tazarotene drug variants containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYLATED HYDROXYTOLUENE
tazarotene drug variants containing BUTYLATED HYDROXYTOLUENE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing BUTYLATED HYDROXYTOLUENE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
Excipient focus: CAPRYLIC/CAPRIC MONO/DI-GLYCERIDES
tazarotene drug variants containing CAPRYLIC/CAPRIC MONO/DI-GLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Pacific Pharma Inc | tazarotene | 60758-556 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing CAPRYLIC/CAPRIC MONO/DI-GLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
Excipient focus: CARBOMER 1342
tazarotene drug variants containing CARBOMER 1342
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| ALMIRALL LLC | tazarotene | 16110-915 |
| Pacific Pharma Inc | tazarotene | 60758-556 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing CARBOMER 1342
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
Excipient focus: CARBOMER COPOLYMER TYPE A
tazarotene drug variants containing CARBOMER COPOLYMER TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0670 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0764 |
| Mayne Pharma | tazarotene | 68308-745 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing CARBOMER COPOLYMER TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: CARBOMER COPOLYMER TYPE B
tazarotene drug variants containing CARBOMER COPOLYMER TYPE B
| Company | Ingredient | NDC |
|---|---|---|
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing CARBOMER COPOLYMER TYPE B
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0670 |
| >Company | >Ingredient | >NDC |
Excipient focus: CARBOMER HOMOPOLYMER TYPE A
tazarotene drug variants containing CARBOMER HOMOPOLYMER TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing CARBOMER HOMOPOLYMER TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: CARBOMER HOMOPOLYMER TYPE B
tazarotene drug variants containing CARBOMER HOMOPOLYMER TYPE B
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing CARBOMER HOMOPOLYMER TYPE B
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
Excipient focus: CETEARETH-12
tazarotene drug variants containing CETEARETH-12
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing CETEARETH-12
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: DIETHYL SEBACATE
tazarotene drug variants containing DIETHYL SEBACATE
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing DIETHYL SEBACATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: DIISOPROPYL ADIPATE
tazarotene drug variants containing DIISOPROPYL ADIPATE
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing DIISOPROPYL ADIPATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: EDETATE DISODIUM
tazarotene drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL CAPRYLOCAPRATE
tazarotene drug variants containing GLYCERYL CAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| ALMIRALL LLC | tazarotene | 16110-915 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing GLYCERYL CAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL MONO- AND DICAPRYLOCAPRATE
tazarotene drug variants containing GLYCERYL MONO- AND DICAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| Pacific Pharma Inc | tazarotene | 60758-561 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing GLYCERYL MONO- AND DICAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: HEXYLENE GLYCOL
tazarotene drug variants containing HEXYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing HEXYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
Excipient focus: LIGHT MINERAL OIL
tazarotene drug variants containing LIGHT MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing LIGHT MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES
tazarotene drug variants containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0670 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
Excipient focus: METHYLPARABEN
tazarotene drug variants containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: MINERAL OIL
tazarotene drug variants containing MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Bausch Health US LLC | tazarotene | 0187-2098 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLOXAMER 407
tazarotene drug variants containing POLOXAMER 407
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing POLOXAMER 407
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
tazarotene drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 40
tazarotene drug variants containing POLYSORBATE 40
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing POLYSORBATE 40
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
Excipient focus: POTASSIUM CITRATE
tazarotene drug variants containing POTASSIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing POTASSIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: POTASSIUM SORBATE
tazarotene drug variants containing POTASSIUM SORBATE
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing POTASSIUM SORBATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLPARABEN
tazarotene drug variants containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
tazarotene drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM THIOSULFATE
tazarotene drug variants containing SODIUM THIOSULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing SODIUM THIOSULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Bausch Health US LLC | tazarotene | 0187-2098 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| >Company | >Ingredient | >NDC |
Excipient focus: SORBIC ACID
tazarotene drug variants containing SORBIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing SORBIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITAN MONOOLEATE
tazarotene drug variants containing SORBITAN MONOOLEATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing SORBITAN MONOOLEATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL
tazarotene drug variants containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
Excipient focus: TROMETHAMINE
tazarotene drug variants containing TROMETHAMINE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing TROMETHAMINE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| E Fougera & Co a division of Fougera Pharmaceuticals Inc | tazarotene | 0168-0455 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
tazarotene drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Fougera Pharmaceuticals Inc | tazarotene | 0168-0454 |
| >Company | >Ingredient | >NDC |
tazarotene drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
